Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem, Inc. (Verastem Oncology, Nasdaq: VSTM) is a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, and its news flow reflects both commercial progress and active clinical development. Company press releases emphasize the U.S. launch and ongoing adoption of AVMAPKI FAKZYNJA CO-PACK, an FDA-approved combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer, as well as updates on confirmatory and expansion trials built around this therapy.
Investors following VSTM news can expect regular updates on clinical trial milestones, including the Phase 3 RAMP 301 confirmatory study in recurrent LGSOC, the RAMP 205 trial in first-line metastatic pancreatic cancer, and the now-discontinued RAMP 203 study in KRAS G12C-mutated NSCLC. Verastem also issues detailed communications on early-stage programs such as VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, covering dose-escalation progress, preliminary safety and efficacy signals, and combination strategies with agents like cetuximab.
Beyond clinical data, Verastem’s news includes capital markets events such as public offerings of common stock and pre-funded warrants, as well as corporate updates on leadership changes and participation in healthcare and investor conferences. These announcements provide context on how the company is funding and prioritizing its RAS/MAPK-focused portfolio.
Stock Titan’s VSTM news page aggregates these company-issued releases and related coverage into a single, organized feed. Readers can use this page to track developments in AVMAPKI FAKZYNJA CO-PACK commercialization, monitor progress of key trials like RAMP 301 and VS-7375-101, and follow Verastem’s financing and strategic communications over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Verastem Oncology (Nasdaq: VSTM) has announced the selection of an abstract detailing interim results from its RAMP 201 trial on avutometinib and defactinib in low-grade serous ovarian cancer (LGSOC) for presentation at the ASCO Annual Meeting on June 2–6, 2023, in Chicago, IL. The trial aims to determine the optimal treatment regimen for LGSOC, characterized by limited options and high recurrence rates. The expansion phase is fully enrolled, focusing on assessing the efficacy and safety of the selected regimen.
The FDA has granted Breakthrough Therapy designation for the combination treatment, which could become the first approved therapy specifically targeting LGSOC. Discussions with the FDA on confirmatory studies are ongoing, with plans for further enrollment in the combination arm of the trial.
Verastem Oncology (Nasdaq: VSTM) has announced its participation in the Stifel 2023 Virtual Targeted Oncology Days, scheduled for April 25, 2023, at 2:30 p.m. ET. During the event, the company will present advancements in biopharmaceuticals aimed at treating cancer patients. A live webcast will be accessible on the company's website, www.verastem.com, with an archived replay available for 90 days after the event.
Verastem focuses on developing novel small molecule drugs targeting critical pathways that enable cancer cell survival and growth, specifically through RAF/MEK and FAK inhibition. For further details on their innovative pipeline and initiatives, visit their website.
Verastem Oncology (Nasdaq: VSTM) granted stock options for 17,000 shares to a new employee as part of an inducement to accept their position. The options have an exercise price of $0.39 per share, equivalent to the company's closing stock price on April 3, 2023. Vesting will occur at a rate of 25% on the one-year anniversary of hire, with the remainder vesting quarterly over three years. Verastem focuses on developing new cancer therapies, targeting crucial pathways to hinder tumor growth.
Verastem Oncology has launched a new initiative titled Let’s Talk About LGSOC, aimed at raising awareness of low-grade serous ovarian cancer (LGSOC). Unlike its high-grade counterpart, LGSOC affects younger women and is associated with limited treatment options. The initiative offers essential information on LGSOC, including its distinct symptoms, and aims to connect patients and support networks. The median age of diagnosis is 45-55, and the disease often shows resistance to chemotherapy, with 85% recurrence post-remission. The initiative is designed to address the lack of dedicated resources for this under-investigated cancer type.